A phase 1 clinical trial included 4 R/R MCL cases who received rituximab in combination with CD47-targeting ALX148 (decoy receptor fusion protein composed of SIRPα N-terminal D1 domain and been mutated for increasing its affinity for CD47 binding). The gene discussed is CD47; the disease is mantle cell lymphoma.